Callisto Pharmaceuticals Files IND For SP-304 (Guanilib) In Chronic Constipation And Irritable Bowel Syndrome
Apr 11th 2008Drug InformationIrritable-Bowel Syndrome
Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4) announced that through its wholly-owned subsidiary, Synergy Pharmaceuticals, Inc. it filed an IND on April 2, 2008 with the FDA for SP-304 (also called Guanilib) for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. SP-304 is an analog of uroguanylin, a natural hormone produced in the gastro-intestinal (GI) tract that is a key regulator of intestinal function.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
